Baba Yuta, Tajima Kohei, Yoshimura Kiyoshi
Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Division of Hematology, Department of Medicine, Showa Medical University Fujigaoka Hospital, Kanagawa, Japan.
Gut Microbes. 2025 Dec;17(1):2505118. doi: 10.1080/19490976.2025.2505118. Epub 2025 May 16.
Esophageal cancer (EC) is the eleventh most commonly diagnosed cancer, and its prognosis remains poor. Several challenges remain for improving the clinical outcomes of EC, and improving technologies for early detection, diversifying treatment options, and advancing personalized treatment are essential. Alterations in the intestinal and esophageal microbiota are associated with the pathogenesis and progression of EC; for instance, is important in the pathogenesis and progression of esophageal squamous cell carcinoma. Therefore, a novel diagnostic biomarker may be identified using the intestinal microbiota. Furthermore, targeting the intestinal and esophageal microbiota may help in the early detection of EC, use of a novel prognostic biomarker, and even the detection of a therapeutic target, resulting in a more individualized therapeutic approach for EC. In this review, we summarize the clinical research focused on the intestinal and esophageal microbiota in EC development and its treatment, and discuss the challenges in the clinical application of intestinal and esophageal microbiota.
食管癌（EC）是第十一种最常被诊断出的癌症，其预后仍然很差。在改善食管癌的临床结果方面仍存在若干挑战，改进早期检测技术、使治疗选择多样化以及推进个性化治疗至关重要。肠道和食管微生物群的改变与食管癌的发病机制和进展相关；例如，在食管鳞状细胞癌的发病机制和进展中很重要。因此，可利用肠道微生物群鉴定一种新型诊断生物标志物。此外，针对肠道和食管微生物群可能有助于食管癌的早期检测、使用新型预后生物标志物，甚至检测治疗靶点，从而为食管癌带来更个体化的治疗方法。在本综述中，我们总结了聚焦于肠道和食管微生物群在食管癌发生发展及其治疗中的临床研究，并讨论了肠道和食管微生物群临床应用中的挑战。
Zotero 插件
